Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer

Galina Semenova, Sander B. Frank, Ruth Dumpit, Wanting Han, Ilsa Coleman, Roman Gulati, Canan D. Dirican, Tarana Arman, Jessica Maruwan, Colm Morrissey, Michael C. Haffner, Peter S. Nelson, John K. Lee

Open source

DOI
10.1172/jci200438
Published
2026-06-23
Container
Journal of Clinical Investigation
Publisher
American Society for Clinical Investigation
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1172/jci200438,
  title = {Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer},
  author = {Galina Semenova and Sander B. Frank and Ruth Dumpit and Wanting Han and Ilsa Coleman and Roman Gulati and Canan D. Dirican and Tarana Arman and Jessica Maruwan and Colm Morrissey and Michael C. Haffner and Peter S. Nelson and John K. Lee},
  year = {2026},
  journal = {Journal of Clinical Investigation},
  doi = {10.1172/jci200438},
  url = {https://doi.org/10.1172/jci200438}
}

RIS

TY  - JOUR
TI  - Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer
AU  - Galina Semenova
AU  - Sander B. Frank
AU  - Ruth Dumpit
AU  - Wanting Han
AU  - Ilsa Coleman
AU  - Roman Gulati
AU  - Canan D. Dirican
AU  - Tarana Arman
AU  - Jessica Maruwan
AU  - Colm Morrissey
AU  - Michael C. Haffner
AU  - Peter S. Nelson
AU  - John K. Lee
PY  - 2026
JO  - Journal of Clinical Investigation
DO  - 10.1172/jci200438
UR  - https://doi.org/10.1172/jci200438
ER  - 

APA

Semenova, G., Frank, S. B., Dumpit, R., Han, W., Coleman, I., Gulati, R., Dirican, C. D., Arman, T., Maruwan, J., Morrissey, C., Haffner, M. C., Nelson, P. S., & Lee, J. K. (2026). Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer. Journal of Clinical Investigation. https://doi.org/10.1172/jci200438

Source records